Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)
Others
Ratios

Benitec Biopharma (BNTC) Net Income towards Common Stockholders (2019 - 2025)

Benitec Biopharma's Net Income towards Common Stockholders history spans 7 years, with the latest figure at -$9.4 million for Q1 2025.

  • For Q1 2025, Net Income towards Common Stockholders fell 118.6% year-over-year to -$9.4 million; the TTM value through Mar 2025 reached -$28.7 million, down 29.17%, while the annual FY2024 figure was -$22.4 million, 14.35% down from the prior year.
  • Net Income towards Common Stockholders for Q1 2025 was -$9.4 million at Benitec Biopharma, up from -$9.6 million in the prior quarter.
  • Across five years, Net Income towards Common Stockholders topped out at -$3.5 million in Q1 2022 and bottomed at -$9.6 million in Q4 2024.
  • The 5-year median for Net Income towards Common Stockholders is -$4.7 million (2022), against an average of -$5.4 million.
  • The largest annual shift saw Net Income towards Common Stockholders increased 23.03% in 2024 before it plummeted 118.6% in 2025.
  • A 5-year view of Net Income towards Common Stockholders shows it stood at -$4.8 million in 2021, then fell by 15.95% to -$5.6 million in 2022, then fell by 20.98% to -$6.8 million in 2023, then plummeted by 40.51% to -$9.6 million in 2024, then increased by 2.07% to -$9.4 million in 2025.
  • Per Business Quant, the three most recent readings for BNTC's Net Income towards Common Stockholders are -$9.4 million (Q1 2025), -$9.6 million (Q4 2024), and -$5.1 million (Q3 2024).